Adlai Nortye (ANL) Competitors $1.57 +0.06 (+3.97%) Closing price 03:59 PM EasternExtended Trading$1.53 -0.04 (-2.55%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. LRMR, CRGX, DSGN, SLS, KOD, MDWD, SCPH, ACIU, ELDN, and TVRDShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Larimar Therapeutics (LRMR), CARGO Therapeutics (CRGX), Design Therapeutics (DSGN), SELLAS Life Sciences Group (SLS), Kodiak Sciences (KOD), MediWound (MDWD), scPharmaceuticals (SCPH), AC Immune (ACIU), Eledon Pharmaceuticals (ELDN), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Larimar Therapeutics CARGO Therapeutics Design Therapeutics SELLAS Life Sciences Group Kodiak Sciences MediWound scPharmaceuticals AC Immune Eledon Pharmaceuticals Tvardi Therapeutics Adlai Nortye (NASDAQ:ANL) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Which has more volatility & risk, ANL or LRMR? Adlai Nortye has a beta of -0.95, suggesting that its stock price is 195% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Which has stronger valuation & earnings, ANL or LRMR? Adlai Nortye has higher revenue and earnings than Larimar Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M11.59-$51.87MN/AN/ALarimar TherapeuticsN/AN/A-$80.60M-$1.49-2.12 Do analysts prefer ANL or LRMR? Adlai Nortye currently has a consensus target price of $9.00, suggesting a potential upside of 473.25%. Larimar Therapeutics has a consensus target price of $18.50, suggesting a potential upside of 485.44%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media prefer ANL or LRMR? In the previous week, Adlai Nortye had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 2 mentions for Adlai Nortye and 1 mentions for Larimar Therapeutics. Adlai Nortye's average media sentiment score of 1.24 beat Larimar Therapeutics' score of 0.94 indicating that Adlai Nortye is being referred to more favorably in the media. Company Overall Sentiment Adlai Nortye Positive Larimar Therapeutics Positive Is ANL or LRMR more profitable? Adlai Nortye's return on equity of 0.00% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Larimar Therapeutics N/A -52.48%-46.08% Do insiders & institutionals hold more shares of ANL or LRMR? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryLarimar Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.93M$2.90B$5.53B$9.30BDividend YieldN/A2.43%4.59%4.02%P/E RatioN/A20.2228.5619.60Price / Sales11.59187.07361.1874.27Price / CashN/A41.0524.7327.56Price / Book2.287.618.155.55Net Income-$51.87M-$55.11M$3.24B$257.73M7 Day Performance-0.63%7.56%2.02%0.95%1 Month Performance-6.82%11.47%8.28%10.68%1 Year Performance-55.03%0.89%28.40%15.67% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.1163 of 5 stars$1.57+4.0%$9.00+473.2%-53.5%$57.93M$5M0.00127News CoveragePositive NewsGap UpLRMRLarimar Therapeutics2.0014 of 5 stars$3.43+7.3%$18.50+438.9%-67.1%$219.88MN/A-2.3030CRGXCARGO Therapeutics2.2283 of 5 stars$4.56+3.8%$15.00+229.3%-74.1%$210.03MN/A-0.99116Gap UpHigh Trading VolumeDSGNDesign Therapeutics0.5441 of 5 stars$3.69+4.1%$4.00+8.5%-8.3%$209.20MN/A-3.7240SLSSELLAS Life Sciences Group0.3345 of 5 stars$2.10-3.5%N/A+70.7%$208.04M$1M-5.4910KODKodiak Sciences4.0566 of 5 stars$3.94+6.2%$9.00+128.4%+72.3%$207.87MN/A-1.0990Gap UpMDWDMediWound1.8504 of 5 stars$19.23-0.2%$31.80+65.4%-3.3%$207.84M$19.21M-9.2080News CoverageSCPHscPharmaceuticals4.4257 of 5 stars$3.93+1.8%$14.00+256.2%-1.1%$207.47M$36.33M-2.0630News CoveragePositive NewsACIUAC Immune2.2043 of 5 stars$2.02+1.6%$12.00+493.8%-42.9%$203.83M$31.02M-3.50140News CoveragePositive NewsAnalyst RevisionGap UpELDNEledon Pharmaceuticals1.8292 of 5 stars$3.41+9.6%$9.00+163.9%+53.9%$202.39MN/A-1.6110News CoverageAnalyst RevisionTVRDTvardi TherapeuticsN/A$21.510.0%$71.50+232.4%N/A$201.33M$7.14M0.0080News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Larimar Therapeutics Alternatives CARGO Therapeutics Alternatives Design Therapeutics Alternatives SELLAS Life Sciences Group Alternatives Kodiak Sciences Alternatives MediWound Alternatives scPharmaceuticals Alternatives AC Immune Alternatives Eledon Pharmaceuticals Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts